Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Harmless virus may hold key to safer kidney transplants

NCT ID NCT06829719

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether monitoring levels of a harmless virus called TTV can help doctors personalize immune-suppressing drugs for kidney transplant patients. The goal is to prevent long-term complications like infections, cancer, and organ rejection. About 600 adults who received a kidney transplant 1-4 years ago will take part. Their treatment will be adjusted based on TTV levels, aiming to find the right balance between preventing rejection and avoiding side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Feb 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult ≥ 18 years-old * Recipient of a kidney allograft (third graft at most) * 12 to 48 months post-transplantation * Stable graft function (defined as: delta creatininemia over the previous 6 months \< 20% and proteinuria \< 30mg/mmol) * On maintenance immunosuppression, which includes CNI (cyclosporin or tacrolimus) and MMF (Cellcept or Myfortic) with or without corticosteroids * Detectable TTV DNAemia at enrollment * No circulating DSA in solid phase assay * Undetectable BKV DNAemia at enrollment * Written informed consent Exclusion Criteria: * Recipient of an HLA identical graft * Mutiple organ transplantation or functional transplant other than kidney * Maintenance immunosuppression that includes a mTOR inhibitor, belatacept or imurel * Presence of histological sign of active rejection (i+t \> 2 and g+cpt \> 2) on graft biopsy performed within 3 months before enrollment * Uncontrolled infection at inclusion * Infection requiring hospitalization within 3 months before inclusion * Diagnosis of a cancer of interest between the (current) transplantation and inclusion * Pregnant, unwillingness to practice adequate contraception or patient with a pregnancy plan during 3 years of study * Person not affiliated to a social security scheme or beneficiary of a similar scheme * Person subject to a legal protection measure (guardianship, curatorship) or deprived of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections neoplasm Rejection, Psychology transplant rejection cancer prevention target infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Infection Kidney transplantation Rejection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Département de Néphrologie et Transplantation d'Organes Hôpital Rangueil - CHU de Toulouse

    RECRUITING

    Toulouse (France), 31059, France

  • Service de Néphrologie, Dialyse et Transplantation Rénale Nouvel Hôpital Civil

    NOT_YET_RECRUITING

    Strasbourg (france), 67091, France

  • Service de Néphrologie-Transplantation-Dialyse I Hôpital Pellegrin I - CHU Bordeaux

    NOT_YET_RECRUITING

    Bordeaux (France), 33000, France

  • Service de transplantation, néphrologie et immunologie clinique Hospices Civils de Lyon, Hôpital Edouard Herriot

    RECRUITING

    Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.